Pembrolizumab Promising in Previously Treated Gastric Cancer Pembrolizumab Promising in Previously Treated Gastric Cancer
In patients with advanced gastric or gastro-esophageal cancer progressing after second-line treatment, monotherapy with pembrolizumab offers a “ promising new treatment option, ” according to research from Merck, which sells the drug as Keytruda.Reuters Health Information
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
More News: Cancer | Cancer & Oncology | Esophagus Cancer | Gastric (Stomach) Cancer | Gastroenterology | Health | Hematology | Merck